On January 12, 2026, the completion of a significant clinical study evaluating advanced therapies for diabetic peripheral neuropathy (DPN) was announced. Conducted by the University of Sao Paulo in collaboration with the Universidade Federal de Sao Carlos, the trial tested two device-based interventions: one active and another as a sham comparator. This announcement signals progress in addressing DPN, a common complication of Type 2 Diabetes Mellitus.
What changed?
Researchers have completed a trial exploring the effectiveness of photobiomodulation and ultrasonic therapy devices for the management of DPN. This condition, frequently seen in individuals with Type 2 Diabetes Mellitus, presents substantial challenges, including pain, mobility issues, and an increased risk of injuries. The trial contributes to identifying viable therapeutic approaches, informing clinical and regulatory stakeholders worldwide.
Study details and methods
The trial employed a rigorous double-arm design to assess device efficacy. Participants were divided into two groups: one exposed to the active intervention and the other to a sham device functioning as a control arm. By employing precise methodology, the research teams sought to determine the comparative benefits and limitations of the tested approaches in alleviating symptoms of DPN.
Clinical significance of findings
The conclusion of this clinical study may inform future regulatory pathways for therapeutic devices targeting diabetic neuropathies. Photobiomodulation and ultrasonic devices are promising non-pharmacological options; their efficacy and safety are critical determinants for market approval. While specific study outcomes have not been explicitly detailed, the alignment of this trial with global standards improves the potential for their adoption in therapeutic protocols.
FAQ
-
What devices were tested in this study?
The trial investigated a photobiomodulation therapy device and an ultrasonic therapy device. A sham group served as a control.
-
Who conducted the study?
The trial was led by the University of Sao Paulo and the Universidade Federal de Sao Carlos.
-
What condition does this trial address?
This trial focused on therapies for diabetic peripheral neuropathy, a complication of Type 2 Diabetes Mellitus.
Conclusion
The successful completion of this clinical trial represents a step forward in managing diabetic peripheral neuropathy using device-based therapies. Regulatory stakeholders, clinicians, and device manufacturers should monitor developments to understand potential implications for future device approvals and therapeutic guidelines.
Disclaimer
This article is for informational purposes for professionals. It does not constitute legal or regulatory advice.
Full announcement
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07317284?term=medical+device